Bictegravir/emtricitabine/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials
-
Published:2023-05
Issue:
Volume:59
Page:101991
-
ISSN:2589-5370
-
Container-title:eClinicalMedicine
-
language:en
-
Short-container-title:eClinicalMedicine
Author:
Sax Paul E., Arribas José R.ORCID, Orkin Chloe, Lazzarin Adriano, Pozniak Anton, DeJesus Edwin, Maggiolo Franco, Stellbrink Hans-Jürgen, Yazdanpanah Yazdan, Acosta Rima, Huang Hailin, Hindman Jason T., Martin Hal, Baeten Jared M., Wohl David
Reference21 articles.
1. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV,2022 2. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the International Antiviral Society-USA Panel;Saag;JAMA,2020 3. Major revision version 11.0 of the European AIDS clinical society guidelines 2021;Ryom;HIV Med,2022 4. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial;Gallant;Lancet,2017 5. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial
Cited by
26 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|